Navigation Links
BioMS Medical announces its intention to renew a normal course issuer bid
Date:9/3/2008

Toronto Stock Exchange Symbol: MS

EDMONTON, Sept. 3 /PRNewswire-FirstCall/ - BioMS Medical Corp (TSX: MS) a leading developer in the treatment of multiple sclerosis (MS), announced today that it is renewing its normal course issuer bid. Under the bid, which will be conducted pursuant to the rules of the Toronto Stock Exchange ("TSX"), the Company may purchase up to 1,000,000 of its Class A common shares (the "Common Shares") representing approximately 1.1% of the Company's issued and outstanding Common Shares.

The bid will commence September 8, 2008 and will expire September 7, 2009 or such earlier date as the Company may complete its purchases. The price at which the Company will purchase its shares will be the market price thereof at the time of acquisition. Purchases of Common Shares will be made in the open market through the facilities of the TSX. Any Common Shares acquired by the Company will be cancelled. The Company has 91,180,923 Common Shares issued and outstanding as of August 27, 2008. During the previous 12 months, the Company acquired 343,300 of its Common Shares at an average price of $3.37 per share by way of a normal course issuer bid. The average daily trading volume of the Common Shares on the TSX (exclusive of purchases under the Company's previous normal course issuer bid) for the period February 1, 2008 to July 31, 2008 was 78,945 shares. Daily purchases will be limited to 19,736 Common Shares, other than block purchase exceptions.

The Board of Directors of the Company believes that the market price of the Common Shares may not fully reflect the value of the Company's business and its future business prospects. As a result, the Board has concluded that the purchase and cancellation of the Common Shares may represent an appropriate and desirable use of the Company's funds and provide market stability.

About BioMS Medical Corp.

BioMS Medical is a biotechnology company engaged in the development and commer
'/>"/>

SOURCE BioMS Medical Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. BioMS Medical announces its intention to renew a normal course issuer bid
2. BioMS Medical to present at BioContact 2007
3. BioMS Medicals relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board
4. BioMS Medical achieves enrollment milestone in U.S. phase III multiple sclerosis trial
5. BioMS Medical announces third quarter 2007 results
6. BioMS Medicals phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board
7. BioMS Medicals pivotal international multiple sclerosis trial receives positive review from Data Safety Monitoring Board
8. Lilly and BioMS Medical Announce Global Licensing and Development Agreement
9. BioMS Medical to present at BIO CEO & Investor Conference
10. BioMS Medical Announces 2007 Year End Results
11. BioMS Medical to present at BioCentury Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... ... , ... In recent years, biodegradable plastics have found wide ... and compostability. These properties can help in limiting the degradation of the enviorment ... the market for biodegradable plastics can be broadly segmented into packaging, fibers, agriculture, ...
(Date:8/31/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/cbgl72/middle_east_and ) ... & Africa Biomedical Sensors Market - Growth, Trends & ... The Middle East & ... by 2018 at a CAGR of 3.26% over the ... Biomedical sensors that are adaptable to the genetic formulation ...
(Date:8/31/2015)... and SHANGHAI , ... privately-held biopharmaceutical company developing next-generation antibiotics, today announced ... clinical study for its lead drug candidate MRX-I. ... treat drug-resistant bacteria such as MRSA and VRE, ... better tolerated therapeutic option than currently available oxazolidinone ...
(Date:8/31/2015)... ... 31, 2015 , ... The Food Processing Suppliers Association's PROCESS ... equipment manufacturers and leaders in the field of academia. , METTLER TOLEDO ... manufacturers of bakery and snacks; beverages; dairy; meat, poultry and seafood; and prepared ...
Breaking Biology Technology:Biodegradable Plastics Market Growing at 10.8% CAGR to 2020 2Biodegradable Plastics Market Growing at 10.8% CAGR to 2020 3Biodegradable Plastics Market Growing at 10.8% CAGR to 2020 4Biodegradable Plastics Market Growing at 10.8% CAGR to 2020 5Middle East & Africa Biomedical Sensors Market Report 2015 - Growth, Trends & Forecasts to 2020 2MicuRX Reports Positive Top-Line Results In Phase 2 Clinical Trial For Novel Antibiotic MRX-I In Complicated Skin And Soft Tissue Infections 2METTLER TOLEDO Hosts Food Safety Educational Center at 2015 PROCESS EXPO 2
... 6, 2011 Van Andel Education Institute (VAEI) has ... to cooperatively recruit students interested in research training in ... genetic biology of human disease.    Under ... will work together to recruit qualified students at historically ...
...  Research Corporation for Science Advancement ( www.rescorp.org ), ... wholly to science, and the second-oldest overall (after ... its Honorary Centennial Observance Committee. The Committee, which ... 2012, is comprised of some of the most ...
... Inc. (Nasdaq: ECTE ), a company developing ... continuous glucose monitoring (tCGM) system and the Prelude® SkinPrep ... from its clinical study of its Symphony tCGM System ... Data from the study confirm that Symphony successfully monitors ...
Cached Biology Technology:Van Andel Institute Partners with UNCF to Recruit Students to Biomedical Research Careers 2Leaders in Science Join Upcoming Celebration of the 100th Anniversary of the Oldest Science Foundation in America 2Echo Therapeutics Announces Positive Results of Clinical Trial of its Symphony® Transdermal Continuous Glucose Monitoring (tCGM) System in Patients With Type 1 and Type 2 Diabetes 2Echo Therapeutics Announces Positive Results of Clinical Trial of its Symphony® Transdermal Continuous Glucose Monitoring (tCGM) System in Patients With Type 1 and Type 2 Diabetes 3Echo Therapeutics Announces Positive Results of Clinical Trial of its Symphony® Transdermal Continuous Glucose Monitoring (tCGM) System in Patients With Type 1 and Type 2 Diabetes 4
(Date:8/25/2015)... LAKE CITY and BELLEVUE, Wash. ... global leader in advanced robotic systems, announced today it ... robotic unmanned ground vehicle (UGV), at the National Tactical ... City.  The Guardian S is the ... the culmination of years of research and in-field trials ...
(Date:8/20/2015)... ., Aug. 20, 2015 NXT-ID, Inc. ... biometric authentication company focused on the growing mobile commerce ... it has joined The Smart Card Alliance and the ... Card Alliance and the Smart Card Alliance Latin America ... to industry peers and thought leaders promoting adoption of ...
(Date:8/12/2015)... 12, 2015   MedNet Solutions , an innovative ... of clinical research, is proud to announce that ... SaaS-based eClinical technology platform, has led the way to ... quarters of 2015.   Q2 2015 and Q1 2015 ... by contract value sold in the company,s 15 year ...
Breaking Biology News(10 mins):Sarcos to Debut First-of-its-Kind Snake Robot 2Sarcos to Debut First-of-its-Kind Snake Robot 3NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 2NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 3NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 4MedNet Solutions Experiences Explosive Corporate Growth 2
... diverse potential applications include the development of ... coatings for medical implants, coatings for semiconductors, ... materials, microelectronics and responsive nanomaterials, and surface-sensitive ... The patented technology stems from the discovery ...
... have contended for millennia that burning incense is good ... is good for our brains too. In a new ... ), an international team of scientists, including researchers from ... describe how burning frankincense (resin from the Boswellia plant) ...
... First identified in 1899, y-larvae have been one of ... one has ever found an adult of these puzzling ... leading generations of marine zoologists to wonder just what ... in BioMed Centrals open access journal, BMC Biology, reports ...
Cached Biology News:Scripps Research Institute awarded patent for remarkable chemical technology 2Scripps Research Institute awarded patent for remarkable chemical technology 3Scripps Research Institute awarded patent for remarkable chemical technology 4Incense is psychoactive: Scientists identify the biology behind the ceremony 2Clue to mystery crustacean in parasite form 2
... Specificity: This antibody recognizes murine ... cross-react with other related IRF ... with murine IRF7 protein was ... of the 293T cells transfected ...
... PS603. Immunogen: Synthetic phosphopeptide ... the phosphorylated Ser603 residue of ... Specific for synapsin I when ... Reactivity: Rat (positive control: ...
MMP-20 Immunogen: Activated recombinant human MMP-2 Storage: -20 C, Avoid Freeze/Thaw Cycles...
karyopherin alpha2 (2G7)...
Biology Products: